{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-010139","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2023-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.841964+00:00","generated_at":"2026-06-14T22:26:11.458929+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Editas Medicine names Erick Lucera as CFO, replacing Michelle Robertson","bullets":["Erick Lucera appointed EVP and CFO effective May 17, 2023, succeeding Michelle Robertson who stepped down May 16.","Lucera previously CFO at AVEO Pharma; receives $470k base salary, 45% target bonus, and equity grants.","Equity includes option for 155,800 shares, RSU for 77,900 shares, and performance-based PSU for 77,900 shares.","Robertson will transition through Aug 16, 2023, receiving 12 months base salary and COBRA contributions.","Robertson's vested stock option exercise period extended to Aug 16, 2024; release agreement required."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-010139","json":"https://secwatch.observer/filing/0001558370-23-010139.json","markdown":"https://secwatch.observer/filing/0001558370-23-010139.md","text":"https://secwatch.observer/filing/0001558370-23-010139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023010139/0001558370-23-010139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023010139/edit-20230511x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T22:26:11.458929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e1fbfd907","claim":"Erick J. Lucera was appointed as Executive Vice President and Chief Financial Officer at Editas Medicine, Inc..","evidence_excerpt":"On May 16, 2023, Editas Medicine, Inc. (the “Company”) appointed Erick J. Lucera as Executive Vice President and Chief Financial Officer of the Company, effective May 17, 2023, succeeding Michelle Robertson as Executive Vice President and Chief Financial Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023010139/0001558370-23-010139-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"a117e87dd7","claim":"Michelle Robertson departed as Executive Vice President and Chief Financial Officer at Editas Medicine, Inc..","evidence_excerpt":"who stepped down as the Company’s Chief Financial Officer effective May 16, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023010139/0001558370-23-010139-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Executive Vice President and Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}